Health and economic impact of rotavirus vaccination in GAVI-eligible countries

Sun-Young Kim; Sweet, Steve; Slichter, David; Goldie, Sue J.
January 2010
BMC Public Health;2010, Vol. 10, p253
Academic Journal
Background: Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries. Methods: We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios. Results: Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 55% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (~$5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's costeffectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (~94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population. Conclusions: Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable costeffectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.


Related Articles

  • Economic impact of a rotavirus vaccination program in Mexico. Constenla, Dagna; Velázquez, F. Raúl; Rheingans, Richard D.; Antil, Lynn; Cervantes, Yolanda // Pan American Journal of Public Health;Jun2009, Vol. 25 Issue 6, p481 

    Objectives. To evaluate the cost and benefits of a national rotavirus childhood vaccination program in Mexico. Methods. A decision-analysis model was designed to take the Mexican health care system's perspective on a comparison of two alternatives: to vaccinate against rotavirus or not. Using...

  • Defeating Rotavirus? The Global Recommendation for Rotavirus Vaccination. Danchin, Margaret H.; Bines, Julie E. // New England Journal of Medicine;11/12/2009, Vol. 361 Issue 20, p1919 

    The authors comment on an announcement made by the World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization concerning the global recommendation for rotavirus vaccines. The decision of the agency was based on statistics that at least two million children below...

  • Rotavirus Vaccine. Stephenson, Joan // JAMA: Journal of the American Medical Association;7/15/2009, Vol. 302 Issue 3, p246 

    The article focuses on the recommendation issued by a World Health Organization advisory group that rotavirus vaccination should be included in all national immunization programs for children. Rotavirus infection is said to cause 500,000 deaths due to diarrheal disease and two million...

  • Comparative Evaluation of Four Hepatitis B vaccines available in Pakistan: Reactogenecity and Immunogenecity. Hakim, Shazia Tabassum; Nadeem, Sayyada Ghufrana; Kazmi, Shahana Urooj // British Journal of Medical Practitioners;2009, Vol. 2 Issue 2, p30 

    Aim: Main objective of this study was to evaluate the immunogenicity of hepatitis B vaccines commonly available in the Pakistan's market. For this purpose we compared immunogenicity and reactogenicity of four recombinant hepatitis B vaccines in apparently healthy young female volunteers in...

  • Immunization in the spotlight. David, Rachel // Nature Reviews Immunology;Jul2009, Vol. 9 Issue 7, p460 

    The article reports on the recommendations by the World Health Organization (WHO) on the inclusion of a rotavirus vaccine in childhood immunization programmes around the world. It relates that rotavirus disease, which causes diarrhoea and vomiting, is responsible for more than 500,000 deaths per...

  • The Costs Of Scaling Up Vaccination In The World's Poorest Countries. Bishai, David; McQuestion, Michael; Chaudhry, Rochika; Wigton, Alyssa // Health Affairs;Mar/Apr2006, Vol. 25 Issue 2, p348 

    We examine the relationship between country-level average costs and coverage levels for diptheria-pertussis-tetanus (DTP) vaccines. Coverage data are from the World Health Organization, and cost data are from financial sustainability plans filed with the Global Alliance for Vaccines and...

  • Rotavirus Vaccine RIX4414 (Rotariâ„¢) A Pharmacoeconomic Review of its Use in the Prevention of Rotavirus Gastroenteritis in Developing Countries. Plosker, Greg L. // PharmacoEconomics;2011, Vol. 29 Issue 11, p989 

    This article provides an overview of the clinical profile of rotavirus vaccine RIX4414 (Rotarix_) in the prevention of rotavirus gastroenteritis (RVGE) in developing countries, followed by a comprehensive review of pharmacoeconomic analyses with the vaccine in low- and middle-income countries....

  • Assessment of Postlicensure Safety of Rotavirus Vaccines, with Emphasis on Intussusception. Bines, Julie E.; Patel, Manish; Parashar, Umesh // Journal of Infectious Diseases;11/2/2009, Vol. 200 Issue S1, pS282 

    The global implementation of rotavirus vaccines will result in a major step toward limiting the disease burden of rotavirus infection. However, as history has shown with the experience of Rotashield (Wyeth Lederle Vaccines), the introduction of a new vaccine should occur in parallel with a...

  • Uptake of Rotavirus Vaccine and National Trends of Acute Gastroenteritis among Children in Nicaragua. Orozco, Maribel; Vasquez, Joshua; Pedreira, Cristina; De Oliveira, Lucia Helena; Amador, Juan José; Malespin, Omar; Andrus, Jon; Tate, Jacqueline; Parashar, Umesh; Patel, Manish // Journal of Infectious Diseases;11/2/2009, Vol. 200 Issue S1, pS125 

    Background. In October 2006, a new rotavirus vaccine was introduced in Nicaragua and was available free to all age-eligible children. We assessed vaccine uptake and trends in acute gastroenteritis (AGE) to assess vaccine impact. Methods. We analyzed national data from the period 2001-2007 on the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics